Claims for Patent: 7,799,783

Summary for Patent: 7,799,783

Title:	Method of administrating an anticancer drug containing .alpha., .alpha., .alpha.-trifluorothymidine and thymidine phosphorylase inhibitor
Abstract:	The present invention relates to a method for treating a cancer comprising orally administering a composition containing .alpha.,.alpha.,.alpha.-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 20 to 80 mg/m.sup.2/day in terms of FTD in 2 to 4 divided portions per to patients in need of the treatment.
Inventor(s):	Emura; Tomohiro (Hanno, JP), Mita; Akira (Tokyo, JP)
Assignee:	Taiho Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:	11/042,059
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,799,783
Patent Claims:	1. A method for treating at least one of a digestive cancer and a breast cancer, comprising orally administering a composition comprising .alpha.,.alpha.,.alpha.-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 50 to 70 mg/m.sup.2/day in terms of FTD in 2 or 3 divided portions per day to a human patient in need of treatment of at least one of a digestive cancer and a breast cancer, wherein the administration of a daily dose of said composition is in 2 or 3 portions per day for 5 days followed by 2 days off treatment in the week on a one-week dosing schedule. 2. The method according to claim 1, further comprising two cycles of administration of a daily dose of said composition in 2 or 3 portions per day for 5 days followed by 2 days off treatment in the week, and subsequent 2 weeks off treatment on a dosing schedule. 3. A method for treating at least one of a digestive cancer and a breast cancer, comprising orally administering a composition comprising .alpha.,.alpha.,.alpha.-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 50 to 70 mg/m.sup.2/day in terms of FTD in 2 or 3 divided portions per day to a human patient in need of treatment of at least one of a digestive cancer and a breast cancer, wherein the .alpha.,.alpha.,.alpha.-trifluorothymidine incorporated into the target site DNA of the cancer one day after the oral administration is present in an amount that is at least a factor of 1.72 greater than the amount of .alpha.,.alpha.,.alpha.-trifluorothymidine incorporated into the target site DNA of the cancer after an equal amount of .alpha.,.alpha.,.alpha.-trifluorothymidine is orally administered in a single dose after one day. 4. A method for treating at least one of a digestive cancer and a breast cancer, comprising: orally administering a composition comprising .alpha.,.alpha.,.alpha.-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 50 to 70 mg/m.sup.2/day in terms of .alpha.,.alpha.,.alpha.-trifluorothymidine in 2 or 3 divided portions per day to a human patient in need of treatment of at least one of a digestive cancer and a breast cancer, wherein the .alpha.,.alpha.,.alpha.-trifluorothymidine incorporated into the target site DNA of the cancer after three days of orally administering the .alpha.,.alpha.,.alpha.-trifluorothymidine is present in an amount that is at least a factor of 1.69 greater than the amount of the .alpha.,.alpha.,.alpha.-trifluorothymidine incorporated into the target site DNA when the oral administration is carried out in a single dose for three days. 5. The method according to claim 3, wherein the composition is orally administered in 3 equally divided portions per day. 6. The method according to claim 4, wherein the composition is orally administered in 3 equally divided portions per day. 7. The method according to claim 1, wherein the cancer is breast cancer. 8. The method according to claim 3, wherein the cancer is breast cancer. 9. The method according to claim 4, wherein the cancer is breast cancer. 10. The method according to claim 1, wherein the cancer is digestive cancer. 11. The method according to claim 3, wherein the cancer is digestive cancer. 12. The method according to claim 4, wherein the cancer is digestive cancer.